[{"id":"7c346db6-4174-4292-8a2b-5cb3e58e0611","acronym":"","url":"https://clinicaltrials.gov/study/NCT05105464","created_at":"2021-11-03T12:53:05.612Z","updated_at":"2024-07-02T16:36:21.590Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05105464","lead_sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","biomarkers":" PD-L1 • FGFR • KDR • CEACAM5 • FGF23","pipe":"","alterations":" ","tags":["PD-L1 • FGFR • KDR • CEACAM5 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SYHA1815"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-11-03"}]